Clinical Trials
24 trialsNCT06694454 2026-06-04
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07234877 2026-06-04
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT04267848 2026-06-03
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04083599 2026-06-02
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04736173 2026-06-01
ARC-10
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT06422143 2026-06-01
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02194738 2026-05-29
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT04092283 2026-05-29
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06333951 2026-05-28
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
Phase 1 Active not recruiting
NCT01993810 2026-05-27
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT06731907 2026-05-26
MK-3475-01G
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT02186847 2026-05-22
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
NCT05800587 2026-05-22
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06312137 2026-05-22
TroFuse-019
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT06712316 2026-05-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
Phase 2/3 Recruiting
NCT04768075 2026-05-20
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
Phase 3 Completed
NCT07599163 2026-05-20
Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase NA Not yet recruiting
NCT04165070 2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06623422 2026-05-15
INTerpath-009
Merck Sharp & Dohme LLC
Phase 3 Recruiting